Publication:
The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data

Simple item page
dc.contributor.authorSALMAN, ANDAÇ
dc.contributor.authorsSalman, Andac; Demir, Gizem; Bekiroglu, Nural
dc.date.accessioned2022-03-12T22:28:42Z
dc.date.available2022-03-12T22:28:42Z
dc.date.issued2019
dc.description.abstractBackground Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). However, the real-life data on the impact of omalizumab on CSU-related quality of life (QoL) remain scarce. Objectives To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU-Q2oL). Results Forty-two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0-1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU-Q2oL scores were lower at the baseline in complete responders (p = .0001). Conclusions A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU-Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.
dc.identifier.doi10.1111/dth.12975
dc.identifier.eissn1529-8019
dc.identifier.issn1396-0296
dc.identifier.pubmed31145524
dc.identifier.urihttps://hdl.handle.net/11424/235323
dc.identifier.wosWOS:000480248400080
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofDERMATOLOGIC THERAPY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectchronic spontaneous urticaria
dc.subjectomalizumab
dc.subjectquality of life
dc.subjectreal-life
dc.subjecttreatment
dc.subjecturticaria
dc.subjectMINIMAL IMPORTANT DIFFERENCE
dc.subjectTURKISH VERSION
dc.subjectMANAGEMENT
dc.subjectPSORIASIS
dc.subjectDIAGNOSIS
dc.subjectIMPROVES
dc.subjectVALIDATION
dc.subjectGUIDELINE
dc.subjectBURDEN
dc.titleThe impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data
dc.typearticle
dspace.entity.typePublication
local.avesis.idaeeb426f-c9a3-49d0-8153-e554e73da783
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumbere12975
local.journal.numberofpages7
local.journal.quartileQ2
oaire.citation.issue4
oaire.citation.titleDERMATOLOGIC THERAPY
oaire.citation.volume32
relation.isAuthorOfPublication22ba329a-4b06-4eb1-8549-b8b32f2d766b
relation.isAuthorOfPublication.latestForDiscovery22ba329a-4b06-4eb1-8549-b8b32f2d766b

Files

Collections

Research Outputs